Observational study of health utilities in adult primary ciliary dyskinesia patients: preliminary data on associations with molecular diagnosis, clinical phenotype and HRQOL measures
暂无分享,去创建一个
K. Kyriacou | P. Yiallouros | M. Loizidou | A. Hadjisavvas | M. Panayiotidis | M. Kakkoura | P. Anagnostopoulou | P. Kouis | P. Ioannou | L. Potamiti | S. Elia | M. Kakkoura
[1] A. Boner,et al. Longitudinal Lung Volume Changes by Ultrastructure and Genotype in Primary Ciliary Dyskinesia. , 2021, Annals of the American Thoracic Society.
[2] K. Kyriacou,et al. Implementation of multigene panel NGS diagnosis in the national primary ciliary dyskinesia cohort of Cyprus: An island with a high disease prevalence , 2021, Human mutation.
[3] Wanqing Chen,et al. Comparing EQ-5D-3L and EQ-5D-5L performance in common cancers: suggestions for instrument choosing , 2020, Quality of Life Research.
[4] P. Yiallouros,et al. Health related quality of life in adult primary Ciliary dyskinesia patients in Cyprus: development and validation of the Greek version of the QOL-PCD questionnaire , 2020, Health and Quality of Life Outcomes.
[5] N. Kiper,et al. Genotype and phenotype evaluation of patients with primary ciliary dyskinesia: First results from Turkey , 2019, Pediatric pulmonology.
[6] A. Quittner,et al. Validation of pediatric health‐related quality of life instruments for primary ciliary dyskinesia (QOL‐PCD) , 2019, Pediatric pulmonology.
[7] K. Kyriacou,et al. Wide phenotypic variability in RSPH9-associated primary ciliary dyskinesia: review of a case-series from Cyprus. , 2019, Journal of thoracic disease.
[8] L. Behan,et al. Translation of the quality-of-life measure for adults with primary ciliary dyskinesia and its application in patients in Brazil , 2019, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.
[9] T. Ferkol,et al. Advances in the Genetics of Primary Ciliary Dyskinesia: Clinical Implications , 2018, Chest.
[10] Liu Liu,et al. Health state utilities and subjective well-being among psoriasis vulgaris patients in mainland China , 2018, Quality of Life Research.
[11] Tobias Welte,et al. Computed tomography in adult patients with primary ciliary dyskinesia: Typical imaging findings , 2018, PloS one.
[12] K. Kyriacou,et al. The effect of l-Arginine on Ciliary Beat Frequency in PCD patients, non-PCD respiratory patients and healthy controls. , 2018, Pulmonary pharmacology & therapeutics.
[13] E. Picard,et al. Clinical impact of Pseudomonas aeruginosa colonization in patients with Primary Ciliary Dyskinesia. , 2017, Respiratory medicine.
[14] J. Yfantopoulos,et al. Validation and comparison of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in Greece , 2017, The European Journal of Health Economics.
[15] B. Karadag,et al. Quality of Life Questionnaire for Turkish Patients with Primary Ciliary Dyskinesia. , 2017, Turkish thoracic journal.
[16] A. Quittner,et al. Validation of a health-related quality of life instrument for primary ciliary dyskinesia (QOL-PCD) , 2017, Thorax.
[17] H. Omran,et al. European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia , 2017, European Respiratory Journal.
[18] B. Housset,et al. Clinical characteristics, functional respiratory decline and follow-up in adult patients with primary ciliary dyskinesia , 2016, Thorax.
[19] D. Hansell,et al. A longitudinal study characterising a large adult primary ciliary dyskinesia population , 2016, European Respiratory Journal.
[20] G. Iskrov,et al. Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe , 2016, The European Journal of Health Economics.
[21] A. Quittner,et al. A quality-of-life measure for adults with primary ciliary dyskinesia: QOL–PCD , 2015, European Respiratory Journal.
[22] Joshua T. Cohen,et al. The changing face of the cost-utility literature, 1990-2012. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[23] M. Rosenfeld,et al. Clinical features of childhood primary ciliary dyskinesia by genotype and ultrastructural phenotype. , 2015, American journal of respiratory and critical care medicine.
[24] Marc Carrier,et al. Validity of standard gamble estimated quality of life in acute venous thrombosis. , 2014, Thrombosis research.
[25] E. Kerem,et al. Differences in disease expression between primary ciliary dyskinesia and cystic fibrosis with and without pancreatic insufficiency. , 2014, Chest.
[26] J. Shendure,et al. Mutations in RSPH1 cause primary ciliary dyskinesia with a unique clinical and ciliary phenotype. , 2014, American journal of respiratory and critical care medicine.
[27] M. Versteegh,et al. Time trade-off: one methodology, different methods , 2013, The European Journal of Health Economics.
[28] M. Boon,et al. Primary ciliary dyskinesia, an orphan disease , 2013, European Journal of Pediatrics.
[29] A. Clément,et al. Longitudinal lung function and structural changes in children with primary ciliary dyskinesia , 2012, Cilia.
[30] J. Bradley,et al. Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study , 2012, European Respiratory Journal.
[31] S. Stanojevic,et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations , 2012, European Respiratory Journal.
[32] A. Bezjak,et al. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers , 2011, Quality of Life Research.
[33] G. Bonsel,et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.
[34] L. Skovgaard,et al. Lung function in patients with primary ciliary dyskinesia: a cross-sectional and 3-decade longitudinal study. , 2010, American journal of respiratory and critical care medicine.
[35] R. Goeree,et al. A review of health utilities across conditions common in paediatric and adult populations , 2010, Health and quality of life outcomes.
[36] A. Boner,et al. Health-related quality of life and unmet needs in patients with primary ciliary dyskinesia , 2009, European Respiratory Journal.
[37] David T Arnold,et al. Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis , 2009, BMJ : British Medical Journal.
[38] W. Dreschler,et al. Choosing between measures: comparison of EQ-5D, HUI2 and HUI3 in persons with hearing complaints , 2007, Quality of Life Research.
[39] Murtuza Bharmal,et al. Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[40] I. Mcmanus,et al. Stigmatization, Physical Illness and Mental Health in Primary Ciliary Dyskinesia , 2006, Journal of health psychology.
[41] D. Niakas,et al. Overcoming inherent problems of preference-based techniques for measuring health benefits: An empirical study in the context of kidney transplantation , 2006, BMC Health Services Research.
[42] I. Mcmanus,et al. Primary ciliary dyskinesia (Siewert's / Kartagener's Syndrome): Respiratory symptoms and psycho-social impact , 2003, BMC pulmonary medicine.
[43] F. Salaffi,et al. Responsiveness of Health Status Measures and Utility-based Methods in Patients with Rheumatoid Arthritis , 2002, Clinical Rheumatology.
[44] J. Tsevat. Response to Lenert and Kaplan: What Do Utilities Measure? , 2000 .
[45] J Tsevat,et al. What do utilities measure? , 2000, Medical care.
[46] A Gafni,et al. The standard gamble method: what is being measured and how it is interpreted. , 1994, Health services research.
[47] E. Nord,et al. The validity of a visual analogue scale in determining social utility weights for health states. , 1991, The International journal of health planning and management.
[48] S. Paisley,et al. How do individuals value health states? A qualitative investigation. , 2017, Social science & medicine.
[49] S. Parlee,et al. This Work Is Licensed under a Creative Commons Attribution-noncommercial 4.0 International License , 2022 .